The majority of NSCLC patients with RET fusion have not yet revealed a clear mechanism of drug resistance, preclinical studies have demonstrated that both RET G810S (178) and RET V804 (179, 180) mutations can confer resistance to RET inhibitors in NSCLC. The gene discussed is RET; the disease is non-small cell lung carcinoma.